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ABSTRACT 
Inserting a Mutation into the Putative Clostridium difficile Bile Salt Hydrolase-Encoding Gene 
 
Natalie Satterfield 
Department of Biology 
Texas A&M University 
 
Research Advisor: Dr. Joseph Sorg 
Department of Biology 
 
Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacterium that causes 
infections in the gastrointestinal tract. The mechanisms by which C. difficile is able to germinate 
in such a toxic environment are not fully understood. However, our lab and others have shown 
that certain bile components have the capacity to induce C. difficile spore germination and affect 
growth of C. difficile cells. Interestingly, C. difficile encodes a bile salt hydrolase (cholylglycine 
hydrolase), but it is unknown how this affects the bacterium’s ability to grow in the presence of 
bile acids. This research project is centered around the goal of inserting a mutation into the C. 
difficile bile salt hydrolase. This will be completed using the TargeTron Gene Knockout 
System, which inserts group II introns into a specific DNA location, and allelic-coupled 
exchange. Successful completion of this project would allow further investigation into the 
relationship between C. difficile’s bile salt hydrolase activity and its ability to grow in the 
presence of bile acids. Ultimately, fully understanding the bacterium’s method of growth could 
help with the development of more effective treatments for C. difficile infections in the future.  
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CHAPTER I 
INTRODUCTION 
 
Clostridium difficile is a spore-forming bacterium that has proven to be a large problem in the 
healthcare environment [1]. C. difficile infects patients who have received antibiotic treatment 
and results in symptoms such as diarrhea, fever, and abdominal pain [1]. Unfortunately, the 
treatment for a C. difficile infection is more antibiotics (e.g. vancomycin or metronidazole) [1]. 
Because these antibiotics further disrupt the colonic microflora, patients frequently relapse with 
C. difficile infections [1]. 
 
When antibiotics are administered to patients, the colonization resistance afforded by the 
colonic microflora is compromised [1]. The loss of colonization resistance provides to C. 
difficile the opportunity to invade and colonize the colonic environment [1]. Upon colonization, 
C. difficile produces two toxins (toxins A and B) that bind to receptors on the cell surfaces of 
epithelial cells [2]. These toxins are then endocytosed and eventually enter the cytosol of these 
cells [2]. By enzymatically glycosylating GTPases, the toxins affect the assembly of cellular 
fibers and the polymerization of actin filaments in epithelial cells [2]. This causes tight 
junctions to deteriorate, and it prevents epithelial cells from attaching to the colonic basement 
membrane, or the lamina propria [2]. Eventually, this leads to apoptosis of the damaged cell [2]. 
Ultimately, this chain reaction leads to inflammation of the intestines, damage to the colonic 
tissues, and diarrhea which spreads C. difficile into the surrounding environment [2].   
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Due to the strict anaerobic nature of C. difficile vegetative cells, C. difficile survives in the 
healthcare environment in the form of a metabolically dominant spore [3]. Spores are dormant 
forms of bacteria that are formed in hostile conditions and are highly resistant to desiccation and 
extreme temperatures [3]. They provide a mechanism of self-protection for bacteria to use in 
conditions that are not ideal for growth [3]. Once environmental conditions improve, bacteria 
are able to respond to the presence of germination-inducing molecules (germinants) to 
germinate into vegetative cells [3]. Structurally, spores contain a core, a dehydrated 
environment containing the genomic DNA, RNA, and essential proteins [3]. Protecting this core 
are various layers composed of phospholipids, proteins, and peptidoglycan, which work to 
provide a defensive barrier between the spore core and the environment [3]. Upon certain 
environmental stimuli that indicate ideal growth conditions, the outer layers of the spore are 
degraded, and the spore core is re-hydrated and a vegetative bacterium grows out from the spore 
[3].  
 
Because of the relative toxicity of the gastrointestinal environment, it is interesting that C. 
difficile has developed a method to survive in such harsh conditions. Our lab has found that the 
germination of C. difficile spores is either activated or inhibited by the presence of certain bile 
acids [4]. For example, glycine and cholate derivatives work to initiate germination of C. 
difficile spores while chenodeoxycholate inhibits cholate-mediated germination [5]. During 
synthesis in the liver, bile acids are conjugated with either glycine or taurine [6]. During 
gastrointestinal transit, bile acids help emulsify fats and cholesterol. Most of the bile acids are 
absorbed by the intestine and recycled back to the liver to be used in other rounds of digestion 
[6]. Here, about 10% of the total bile acids enter the colonic environment where they are acted 
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upon by members of the microbiota [6]. However, these conjugated bile acids are hydrolyzed 
back into their base bile acid molecules by bile salt hydrolases (e.g. taurocholate is 
deconjugated to cholate), which are expressed on the cell surfaces of many members of the 
colonic microbiota [4].  
 
Selective pressure from the toxicity of bile forces only bacteria best suited to the toxic 
environment to survive [7]. Bile salt hydrolases provide multiple benefits to the bacteria that 
express them and are likely a substantial factor that allows some bacteria to survive in the colon 
[7]. For example, bile salt hydrolases often help bacteria obtain nutrition [7]. Amino acids are 
freed when bile salts are deconjugated, and these can be broken down by bacteria to be used as 
sources of energy, carbon, and nitrogen [7]. Therefore, bacteria encoding bile salt hydrolases 
may be more fit than others to survive in nutritionally depleted environments [7]. In addition, 
bile salt hydrolases allow bacteria to alter their cell membranes in order to protect themselves 
from host defense mechanisms [7]. For example, some bacteria utilize their bile salt hydrolase 
activity to add bile acids to their membranes in order to increase the strength of the membrane 
or alter the net charge and fluidity of the membrane [7]. Because these factors affect the 
susceptibility of certain bacteria to host defense mechanisms, membrane modifications may 
provide a means for bacteria to protect themselves from defense systems in the colon [7]. 
Lastly, it has been found that conjugated bile salts, especially glycoconjugated bile salts, are 
very toxic to bacteria due to their ability to acidify intracellular components of microorganisms 
[7]. Therefore, bile salt hydrolases may provide a mechanism of self-defense that protects 
bacteria from the toxicity of bile salts [7].  
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C. difficile encodes a homologue of a bile salt hydrolase (CD2311). Because bile acids impact 
C. difficile germination and growth, I hypothesize that the bile salt hydrolase activity affects C. 
difficile growth in the presence of certain bile acids [4]. In order to test for potential bile salt 
hydrolase activity, it is necessary to first inactivate the gene coding for the bile salt hydrolase in 
C. difficile [8]. While there are multiple methods of gene inactivation that are used on C. 
difficile, this project will use the TargeTron gene knockout system to inactivate CD2311. With 
this system, a group II intron is re-targeted to the CD2311 DNA sequence using a computer 
algorithm [8]. This region is subcloned into our targeting vector and then delivered to C. 
difficile through conjugation [9]. Once expressed in C. difficile, an RNA-protein complex is 
expressed from the cloned plasmid, which retro-homes the TargeTron RNA to the insertion site 
in the genomic DNA, and inserts the RNA sequence using reverse transcription to create double 
stranded DNA [9]. Ideally, this will disrupt the coding sequence of CD2311 [9]. The use of 
group II introns is widely used to inactivate genes in C. difficile today [9]. However, another 
method of gene inactivation in C. difficile is single crossover plasmid integration [9]. With this 
technique, a plasmid is integrated into the genome through a single crossover event during 
homologous recombination [9]. While this method has been successful at producing the desired 
mutants in the past, the insertion is often unstable . Therefore, the use of group II introns is 
often preferred [9].  
 
If C. difficile expresses a bile salt hydrolase, successful insertion of a group II intron into the 
gene encoding the bile salt hydrolase will enable an investigation of the relationship between 
any bile salt hydrolase activity of C. difficile cells and the effects of this on its growth. 
Importantly, if CD2311 is associated with bile acid tolerance in the presence of certain bile 
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acids, it may serve as an effective target for future chemotherapeutic treatment of C. difficile 
infections.  
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CHAPTER II 
METHODS 
 
Bacterial strains and growth conditions 
C. difficile UK1 was grown on brain heart infusion medium containing 5 g/L of yeast extract 
and 0.1% L-cysteine (BHIS) at 37ºC in an anaerobic chamber containing 85% N2, 10% H2, and 
5% CO2 [5].  E. coli DH5α and E. coli MB3436 were grown on Luria-Bertani (LB) medium at 
37ºC aerobically [10]. B. subtilis BS49 was grown on LB medium at 30ºC aerobically. The 
antibiotics chloramphenicol (20 µg/mL for E. coli and 2.5 µg/mL for B. subtilis), thiamphenicol 
(10 µg/mL), tetracycline (5 µg/mL), lincomycin (20 µg/mL), and kanamycin (50 µg/mL) were 
added where necessary [10]. 
 
Generation of group II intron and creation of plasmids 
A computer algorithm (provided by Targetronics, LLC.) determined potential insertion sites for 
a group II intron in C. difficile CD2311, and the insertion fragment was generated as a gBlock 
from Integrated DNA Technologies (IDT) [11]. This 350 base pair fragment was cloned into 
pCR-Blunt II-TOPO and then sub-cloned into the BsrGI and HindIII insertion sites of pJS107, a 
TargeTron vector used to insert mutations into C. difficle UK1, producing pNS02 [11]. pNS02 
was then introduced into B. subtilis BS49 using standard techniques [10].  
 
Conjugation and screening for mutants 
B. subtilis BS49 was used as the donor for conjugation to introduce pNS02 into C. difficile UK1 
using previously described techniques [10]. Colonies that showed thiamphenicol resistance, 
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indicating the presence of the pNS02 plasmid, and tetracycline sensitivity, indicating the 
absence of the Tn916 transposon, were then isolated and re-streaked onto BHIS medium 
containing lincomycin [10]. Lincomycin-resistant colonies indicated potential strains with a 
successful TargeTron insertion into CD2311 [10]. DNA was then isolated from the lincomycin-
resistant colonies by first suspending a single colony in 95 µL of 1X PCR buffer. 4 µL of 
lysozyme (50 mg/mL) were then added to the suspension and incubated at room temperature for 
15 minutes. Next, 1 µL of proteinase K (20 mg/mL) was added, and this incubated at 58ºC for 
60 minutes. Proteinase K was then inactivated at 90ºC for 15 minutes, and the mixture was 
centrifuged at 5000 rpm for 5 minutes. The supernatant was removed and used to screen for the 
insertion into CD2311 using polymerase chain reaction and primers generated specifically for 
CD2311 [10].  
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CHAPTER III 
RESULTS 
 
Generating a site-directed mutation in C. difficile CD2311 
The germination of C. difficile spores within the gastrointestinal tract has been found to be both 
activated and inhibited by the presence of different bile acids, and thus the resulting vegetative 
cells must survive their toxic actions [4,12]. Because CD2311 codes for a protein with potential 
bile salt hydrolase activity, it may play a role in surviving in the host colonic environment. To 
generate a site-directed mutation in C. difficile CD2311, two different TargeTron insertion sites 
were chosen (nt 532 and 583 of 1,170, respectively). If the retargeting algorithm correctly 
predicted the insertion sites, the ~1,800 nt group II intron would be inserted and reverse 
transcribed into the genome, thus disrupting the CD2311 gene sequence (Figure 1) [9].  
 
 
 
Figure 1. Diagram of TargeTron insertion site. Two different TargeTron insertion sites were 
used to retarget the TargeTron to nucleotide 532 or 583 of C. difficile CD2311. 
 
The TargeTron re-targeting sequences were cloned into the C. difficile TargeTron shuttle vector, 
pJS107. The successful introduction of the 532 and 583 nt TargeTron re-targeting fragments 
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into pJS107 was verified using restriction analysis and gel electrophoresis (Figure 2). As a 
control, pJS107 was included in the digest (Lane 2, Figure 2 and Lane 2, Figure 3). In lanes 3 to 
8 of Figures 2 and 3, the digested potential positive clones show a large fragment (12,500 bp) 
corresponding to the vector backbone. Lanes 3 to 8 in Figures 2 and 3 also show a fragment at 
~350 bp, in addition to the vector backbone, which is indicative of the presence of the desired 
insert. Therefore, the gels confirm the successful ligations of pJS107 with the inserts.  
 
 
 
Figure 2. Verification of successful ligation of pJS107 (vector) and nucleotide 532 re-
targeting fragment. Lane 1: 100 bp ladder, lane 2: digested pJS107 with HindIII and BsrGI, 
and lanes 3-8: potential re-targeted isolates digested with HindIII and BsrGI.  
Lane 1 Lane 2 Lane 3 Lane 4 Lane 5 Lane 6 Lane 7 Lane 8 
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Figure 3. Verification of successful ligation of pJS107 (vector) and nucleotide 583 re-
targeting fragment. Lane 1: 100 bp ladder, lane 2: pJS107 digested with HindIII and BsrGI, 
and lanes 3-8: potential re-targeted isolates digested with HindIII and BsrGI.  
 
The re-targeted vectors were introduced into B. subtilis BS49 and then into C. difficile UK1 
using conjugation. After conjugation, plasmid-positive C. difficile UK1 isolates (containing 
pNS02 and pNS04) were streaked onto medium supplemented with lincomycin to select for 
those cells that had the intron insert. DNA from the lincomycin-resistant colonies was isolated 
and screened for the presence of a TargeTron insertion into CD2311 using PCR (Figure 4 and 
Figure 5). Wildtype C. difficile UK1 CD2311 is approximately 1,500 bp in length (Figure 4 and 
Figure 5) and a ~3,300 bp fragment is expected if the intron inserts into the CD2311 gene. 
Amplification of the DNA extracted from each isolate, except for those in lanes 6 and 7 of 
Figure 4 and lane 10 of Figure 5 which show a failed PCR reaction, yield an approximately 
1,500 bp fragment similar to that of the wildtype control. These results suggest that all tested 
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colonies were negative for the CD2311 mutation and that the intron likely inserted elsewhere in 
the genome (a possibility given the nature of the retargeting algorithm).  
 
 
 
Figure 4. Screening for mutations in CD2311 at nucleotide 532. Lane 1: 1 kb ladder, lane 2: 
distilled water, lane 3: E. coli DH5α pNS02, lane 4: E. coli MB3436 pNS02, lane 5: wildtype C. 
difficile UK1, and lanes 6-18: lincomycin-resistant colonies that were screened for the CD2311 
mutant.  
  
  
 
Figure 5. Screening for mutations in CD2311 at nucleotide 583. Lane 1: 1 kb ladder, lane 2: 
distilled water, lane 3: E. coli DH5α pNS04, lane 4: wildtype C. difficile UK1, and lanes 5-14: 
lincomycin-resistant colonies that were screened for the CD2311 mutant.  
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Inactivating CD2311 using Allelic-Coupled Exchange 
Given the difficulties in genetically manipulating C. difficile, we also chose to inactivate 
CD2311 using allelic-coupled exchange (ACE) technology [13]. This method involves the use 
of a vector that is segregationally unstable in C. difficile. By amplifying 1 kb upstream and 
downstream of the gene of interest and piecing the products together, we create a deletion in the 
CD2311 coding region (Figure 6) [13].  
 
 
 
Figure 6. Diagram of CD2311 deletion using allelic exchange. 1 kb upstream of CD2311 and 
1 kb downstream of CD2311 cloned into the allelic exchange vector pMTLSC7215 will yield a 
complete deletion of CD2311 coding sequence upon homologous recombination in the C. 
difficile genome.   
 
The 1 kb upstream and downstream fragments of CD2311 were inserted into the PmeI sites of 
the pMTLSC7215 ACE vector using Gibson assembly, yielding pNS05 [13]. Positive clones 
14 
 
were verified by restriction digest and by PCR (Figure 7). As a control, pMTLSC7215 was 
included in the digest (Lane 2, Figure 7). In lanes 3 to 6 of Figure 7, the digested potential 
positive plasmids show a large fragment corresponding to the pMTLSC7215 vector. Lanes 3 to 
6 of Figure 7 also show fragments at ~2000-2500 bp, in addition to the vector backbone. This 
confirms the presence of the desired plasmid. In lanes 9 to 16 of Figure 7, the PCR reaction 
amplifying the 2 kb C. difficile fragment of the allelic-coupled exchange plasmid show a band at 
~2000-2500 bp. This corresponds to the ~2000-2500 bp fragment shown in lanes 3 to 6 of the 
same figure and further confirms the presence of the desired plasmid. 
 
 
 
Figure 7. Verification of allelic-coupled exchange plasmid. Lane 1: 1 kb ladder, lane 2: E. 
coli DH5α pMTLSC7215 digested with PmeI, lanes 3-6: E. coli DH5α pNS05 digested with 
PmeI, lanes 7-8: E. coli DH5α pMTLSC7215 PCR, lanes 9-16: E. coli DH5α pNS05 PCR.  
 
The resulting plasmid was introduced into E. coli HB101 and then into C. difficile via 
conjugation. Plasmid-positive C. difficile isolates were identified and passaged to identify 
potential single-integrants of the pNS05 plasmid. Due to the plasmid being segregationally 
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unstable in C. difficile, single-integrants appear as a ‘large colony’ phenotype among a small 
colony background. Excision of the plasmid from the C. difficile genome will be induced by 
inoculating onto medium supplemented with 5-fluorocytosine (FC). DNA will be extracted 
from the FC-resistant strains, and the CD2311 coding regions amplified by PCR. Because this 
method results in a deletion in the CD2311 coding region, the resulting potential mutants will be 
amplified using outside primers to detect a smaller fragment compared to a wild-type control.  
 
Following multiple attempts of conjugation, results showed either no colonies or colonies that 
appeared explicitly as ‘small colony’ phenotypes. Therefore, this suggests that no single-
integrants were present and that the allelic-coupled exchange method was also unsuccessful at 
inactivating CD2311.  
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CHAPTER IV 
CONCLUSION 
 
Hospital-acquired C. difficile colitis has become a growing problem to health care providers. In 
the environment, C. difficile exists in its dormant yet highly protective spore form, making the 
bacteria challenging to completely remove from patient facilities and effective at colonizing 
susceptible hosts [14,15]. However, in order to cause symptoms and disease, C. difficile spores 
must first germinate within the colon [11]. Previous research has found that, when tested in 
vitro, bile acids act as activators and inhibitors of C. difficile germination [4,12]. For example, 
glycine and cholate derivatives were found to work as activators of germination [4]. 
Conversely, chenodeoxycholate was found to act as a competitive inhibitor of germination 
mediated by taurocholic acid [12]. Ultimately, the composition of bile acids within the 
gastrointestinal environment plays a critical role in C. difficile spore degradation and vegetative 
cell colonization [4,11,12].  
 
C. difficile encodes a bile salt hydrolase, yet it is currently unknown whether this gene is 
expressed [4]. Given that the bile acid composition of its environment works to optimize growth 
in C. difficile cells, an expressed bile salt hydrolase could play a vital role in maintaining 
infection [4]. If a bile salt hydrolase is expressed, its catalytic activity could provide a 
mechanism that frees nutrients, such as glycine, to aid in vegetative cell growth [16]. 
Ultimately, if expressed, a bile salt hydrolase could influence the makeup of bile acids within 
the human colonic environment and impact a host’s susceptibility to infection.  
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Studying the potential C. difficile bile salt hydrolase is important as it could unveil a possible 
pathway to target that effectively combats the disease. As the bile salt hydrolase would most 
likely affect C. difficile growth, targeting the supposed bile salt hydrolase could provide a 
mechanism to slow or stop vegetative cell growth in patients completely. Ultimately, for future 
directions of this research, efforts should be made to generate a CD2311 mutant, and the 
relationship between any bile salt hydrolase activity and growth should be investigated.  
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